Clinical and Biological Cohort Study of EBV-Positive T/NK-Cell Lymphoproliferative Diseases
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is a multicenter, non-interventional, ambidirectional cohort study of Epstein-Barr virus-positive T/NK-cell lymphoproliferative diseases. The study consists of a retrospective clinical cohort of 500 consecutively diagnosed patients with extranodal NK/T-cell lymphoma and a prospective clinical-biological cohort of 1,000 newly diagnosed patients with extranodal NK/T-cell lymphoma, aggressive NK-cell leukemia, systemic chronic active Epstein-Barr virus disease of T/NK-cell type, or Epstein-Barr virus-positive nodal T/NK-cell lymphoma. The study will characterize clinical features, treatment pathways, response, relapse or progression patterns, and long-term survival. The prospective cohort will additionally undergo standardized collection of peripheral blood and optional tumor tissue specimens at predefined clinical time points. Clinical, molecular, viral, and immune biomarkers will be evaluated for their associations with treatment response, treatment failure, disease progression, and survival. No treatment is assigned by the study.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat
- •Nowo rozpoznana choroba związana z wirusem Epsteina-Barr dotycząca komórek T/NK
- •Dla części retrospektywnej: rozpoznanie między 2017 a 2025 rokiem
- •Dla części prospektywnej: rozpoznanie między czerwcem 2026 a grudniem 2030 roku
- •Dostępne informacje diagnostyczne, wyniki badań i dane o leczeniu
- •Dla części prospektywnej: pisemna zgoda i pobranie próbki krwi na początku badania
✗ Disqualifies
- •Brak informacji o przeżyciu pacjenta lub niemożliwość ustalenia jego statusu
- •Dla części prospektywnej: niemożliwość uczestniczenia w regularnych wizytach kontrolnych
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 13, 2026
- Sex
- No restrictions
Locations (1)
Fudan University Shanghai Cancer Center
Shanghai, China
Trial contact
Rong Tao, MD
Chuanxu Liu, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/14/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.